Onsdag 30 Oktober | 09:25:00 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2026-01-28 08:00 Bokslutskommuniké 2025
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-17 08:00 Kvartalsrapport 2025-Q2
2025-05-06 - Årsstämma
2025-04-23 08:00 Kvartalsrapport 2025-Q1
2025-01-28 08:00 Bokslutskommuniké 2024
2024-10-22 - Kvartalsrapport 2024-Q3
2024-07-16 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning PROB 1.30 SEK
2024-05-07 - Årsstämma
2024-04-23 - Kvartalsrapport 2024-Q1
2024-01-26 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning PROB 1.30 SEK
2023-05-04 - Årsstämma
2023-04-26 - Kvartalsrapport 2023-Q1
2023-01-27 - Bokslutskommuniké 2022
2022-10-21 - Kvartalsrapport 2022-Q3
2022-07-15 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning PROB 1.30 SEK
2022-05-05 - Årsstämma
2022-04-26 - Kvartalsrapport 2022-Q1
2022-02-02 - Bokslutskommuniké 2021
2021-10-22 - Kvartalsrapport 2021-Q3
2021-07-26 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning PROB 1.10 SEK
2021-05-07 - Årsstämma
2021-04-23 - Kvartalsrapport 2021-Q1
2021-02-09 - Bokslutskommuniké 2020
2020-10-21 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-14 - X-dag ordinarie utdelning PROB 1.00 SEK
2020-05-13 - Årsstämma
2020-04-24 - Kvartalsrapport 2020-Q1
2020-02-11 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-07-19 - Kvartalsrapport 2019-Q2
2019-05-08 - X-dag ordinarie utdelning PROB 0.00 SEK
2019-05-07 - Årsstämma
2019-04-29 - Kvartalsrapport 2019-Q1
2019-02-13 - Bokslutskommuniké 2018
2018-11-06 - Kvartalsrapport 2018-Q3
2018-08-13 - Kvartalsrapport 2018-Q2
2018-05-03 - X-dag ordinarie utdelning PROB 0.00 SEK
2018-05-02 - Årsstämma
2018-05-02 - Kvartalsrapport 2018-Q1
2018-01-25 - Bokslutskommuniké 2017
2017-10-25 - Kvartalsrapport 2017-Q3
2017-07-19 - Kvartalsrapport 2017-Q2
2017-05-05 - X-dag ordinarie utdelning PROB 1.00 SEK
2017-05-04 - Kvartalsrapport 2017-Q1
2017-01-24 - Bokslutskommuniké 2016
2016-10-18 - Kvartalsrapport 2016-Q3
2016-07-15 - Kvartalsrapport 2016-Q2
2016-06-29 - Extra Bolagsstämma 2016
2016-04-28 - X-dag ordinarie utdelning PROB 1.00 SEK
2016-04-27 - Kvartalsrapport 2016-Q1
2016-04-27 - Årsstämma
2016-01-26 - Bokslutskommuniké 2015
2015-10-22 - Kvartalsrapport 2015-Q3
2015-07-16 - Kvartalsrapport 2015-Q2
2015-04-24 - X-dag ordinarie utdelning PROB 0.85 SEK
2015-04-23 - Årsstämma
2015-04-23 - Kvartalsrapport 2015-Q1
2015-01-28 - Bokslutskommuniké 2014
2014-10-29 - Analytiker möte 2014
2014-10-29 - Kvartalsrapport 2014-Q3
2014-08-19 - Kvartalsrapport 2014-Q2
2014-04-30 - X-dag ordinarie utdelning PROB 0.75 SEK
2014-04-29 - Kvartalsrapport 2014-Q1
2014-04-29 - Årsstämma
2014-01-23 - Bokslutskommuniké 2013
2013-10-22 - Kvartalsrapport 2013-Q3
2013-08-20 - Kvartalsrapport 2013-Q2
2013-04-25 - X-dag ordinarie utdelning PROB 0.75 SEK
2013-04-24 - Årsstämma
2013-04-24 - Kvartalsrapport 2013-Q1
2013-01-24 - Bokslutskommuniké 2012
2012-10-18 - Kvartalsrapport 2012-Q3
2012-09-28 - Kapitalmarknadsdag 2012
2012-08-16 - Kvartalsrapport 2012-Q2
2012-04-26 - Årsstämma
2012-04-26 - Kvartalsrapport 2012-Q1
2012-01-25 - Bokslutskommuniké 2011
2011-10-19 - Kvartalsrapport 2011-Q3
2011-07-19 - Kvartalsrapport 2011-Q2
2011-04-29 - X-dag bonusutdelning PROB 0.5
2011-04-29 - X-dag ordinarie utdelning PROB 0.50 SEK
2011-04-28 - Årsstämma
2011-04-28 - Kvartalsrapport 2011-Q1
2011-01-26 - Bokslutskommuniké 2010
2010-10-20 - Kvartalsrapport 2010-Q3
2010-07-20 - Kvartalsrapport 2010-Q2
2010-04-23 - X-dag ordinarie utdelning PROB 0.50 SEK
2010-04-22 - Årsstämma
2010-04-22 - Kvartalsrapport 2010-Q1
2010-01-27 - Bokslutskommuniké 2009
2009-10-21 - Kvartalsrapport 2009-Q3
2009-08-18 - Kvartalsrapport 2009-Q2
2009-05-07 - X-dag ordinarie utdelning PROB 0.00 SEK
2009-05-06 - Årsstämma
2009-04-22 - Kvartalsrapport 2009-Q1

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Probi är verksamt inom bioteknik. Bolaget är särskilt inriktade mot forskning och utveckling av probiotika, en god bakterie som återfinns i människans tarmsystem. Forskningsområdena inom bolaget innefattar mag och tarm, immunförsvar, metabola syndrom samt stress och återhämtning. Bland bolagets kunder återfinns större företagskunder inom livsmedelsindustrin. Bolaget grundades under 1991 och har sitt huvudkontor i Lund.
2024-05-07 16:20:00

On Probi's Annual General Meeting on 7 May 2024, the following was resolved:                                 

  • The Annual General Meeting approved the Annual Report and the Board's proposal on a dividend for the financial year 2023 corresponding to SEK 1.30 per share. The record date was set to 10 May 2024.
  • The Annual General Meeting resolved to approve the Board's remuneration report.
  • The Annual General Meeting discharged the Board members and the Chief Executive Officer from liability for the financial year 2023.
  • The Annual General Meeting resolved that the Board shall consist of five members without any deputies. The Annual General Meeting re-elected the Board members Jean-Yves Parisot, Jörn Andreas, Charlotte Hansson and Malin Ruijsenaars and resolved on new election of Stephanie Blum Sperisen as Board member. Jean-Yves Parisot was re-elected as Chairman of the Board.
  • The Annual General Meeting resolved that Board fees shall be paid in the amount of SEK 540,000 (SEK 540,000) to the Chairman and SEK 270,000 (SEK 270,000) to each of the other members. In addition, fee for committee work was determined to SEK 120,000 (SEK 120,000) to the Chairman of the Audit Committee and SEK 50,000 (SEK 50,000) to the other members, and SEK 30,000 (SEK 30,000) to Chairman of the Remuneration Committee and SEK 20,000 (SEK 20,000) to the other members.
  • The Annual General Meeting re-elected the registered public accounting firm Ernst & Young AB, which had informed that Peter Gunnarsson should be the auditor in charge, and resolved on fees to the auditor according to approved account.
  • The Annual General Meeting resolved, in accordance with the Board's proposal, on revised guidelines for remuneration to senior executives.
  • The Annual General Meeting resolved, in accordance with the Board's proposal, to autorize the Board to, for the period until the next Annual General Meeting and on one or several occasions, resolve on the issue of not more than 1,165,000 shares.

Presentation from the CEO is available on https://www.probi.com/investor-relations/presentations/

For further information, please contact:

Anita Johansen, CEO, Telephone: + 46 (0)46 286 89 48, E-mail: anita.johansen@probi.com
Per Lindblad, CFO, Probi, phone +46 46 286 89 41, E-mail: per.lindblad@probi.com

ABOUT PROBI

Probi[®] is a global Group that focuses exclusively on research, manufacturing and delivery of probiotics in dietary supplements and food. The company has expertise in managing live bacteria from research through all stages of the manufacturing process and is dedicated to making the health-promoting benefits of probiotics available to people around the world. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds more than 400 patents worldwide. Probi had sales of SEK 628 m in 2023. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,400 shareholders on December 31, 2023.